INTRODUCTION
Survival after childhood cancer has substantially improved during the past decades, and it is now up to 80% considering all diseases, and nearly 75% of the patients will be living 10 years after diagnosis. 1 The long-term survival rate of children undergoing haematopoietic stem cell transplant (HSCT) for malignant and non-malignant diseases is constantly increasing.
However, it is now well known that improvement in survival presents, on the other hand, an increase in morbidity in long-term survivors. [2] [3] [4] Among all the late effects, infertility is reported as a major concern, especially in female cancer survivors. 5 Cancer treatment often involves aggressive radiotherapy or chemotherapy, which may permanently impair reproductive function. Ovarian damage after HSCT is determined by the conditioning regimen that can include chemotherapy and/or radiotherapy. This effect might be increased by previous exposure to gonadotoxic treatment. 6 In particular, TBI and older age at the time of HSCT can negatively affect the persistence of ovarian function and the onset of premature ovarian failure (POF). [7] [8] [9] When administered before puberty, TBI is less gonadotoxic, with 40-60% of the patients experiencing spontaneous recovery versus 10-14% in postpubertal girls. 6 The protective effect of a younger age might be related to the higher number of nongrowing follicles, 10 to the higher resistance of primordial follicles, to vascular phenomena and fibrosis or to paracrine factors. 11 Moreover, a model has been evaluated to predict the age of onset of menopause according to radiation dose and age at irradiation. 12 Loss of ovarian function after chemotherapy that includes an alkylating agent (cyclophosphamide, busulfan) could result in both infertility and endocrine function deficiency, as ovarian hormonal production is closely related to the presence of oocytes and maturation of the primary follicles. [13] [14] Owing to all these factors, the risk of infertility in patients undergoing conditioning regimen for HSCT has been defined as 480%.
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Fertility preservation is a key component of POF management, and it should be considered for all young girls undergoing potentially gonadotoxic cancer treatments or who are at a high risk for ovarian failure because of genetic and autoimmune diseases.
Cryopreservation of ovarian tissue is still an experimental technique for fertility preservation. It represents the main option available for women who require cancer treatment but cannot delay chemotherapy; moreover it is the only possibility for prepubertal patients. 15 The advantage is that it requires just a few days to plan and perform the laparoscopic surgery and, as the retrieval of ovarian tissue is not dependent on the menstrual cycle, no delay in treatment is required. Moreover, this technique allows the storage of a great number of primordial follicles that are relatively resistant to cryodamage (about 70-80% survival). 16 Since 2000, in our centre, we have enrolled female patients at high risk for subsequent infertility in the 'Fertisave' protocol (ovarian tissue cryopreservation). 1 
PATIENTS AND METHODS
After obtaining the approval of the ethics committee, we proposed ovarian tissue cryostorage to female HSCT candidate patients who were at a high risk of subsequent infertility, to preserve their fertility.
Informed consent was signed by patients or their parents/legal guardians. After clinical and haematological evaluations, the patients were referred to surgery. Ovarian tissue retrieval was frequently scheduled at the same time of another procedure such as bone marrow harvest or the placement of a central line for chemotherapy administration. Ovarian tissue collection was performed by laparoscopic surgery. We collected monolateral or bilateral ovarian cortex biopsies. The amount of cortex to be cut is a compromise between the need to cryopreserve as much tissue as possible and the need to maintain an ovarian volume permitting future transplantation: usually about 50% of ovarian cortex was removed. 17 After retrieval, the ovarian tissue was immediately rinsed in in vitro fertilization (IVF) buffered medium and transported on ice to the IVF laboratory, where the freezing procedure took place. In our centre, rapid transport of the removed tissue to the laboratory was performed. Once the sample reached the IVF laboratory, the ovarian cortex was stored in liquid nitrogen following slow-freezing procedure. 18 Although the ovarian tissue was prepared for cryopreservation, a small piece of the ovarian cortex was sent to a pathologist to evaluate the number and density of primordial follicles and the possible presence of tumor cells. [19] [20] [21] Before performing reimplantation, a small piece of frozenthawed tissue was analysed to check the presence and density of morphologically normal primordial follicles. At the time of transplantation, a small fraction of the bilateral remnant atrophic ovaries was collected in order to detect the possible presence of follicles. The thawing procedure required the removal of cryoprotectant from the ovarian strips. After thawing, the fragments were placed in a Petri dish filled with IVF buffered medium equilibrated at room temperature and carried to the operating room. Transplantation took place into the pelvic cavity (orthotopic transplant).
Data on previous chemo/radiotherapy exposure, conditioning regimen and gonadal function were collected. Hypogonadism was defined as the presence of at least two of three identifying features: primary or secondary amenorrhea, high levels of follicle-stimulating hormone (420 UI/mL) with low levels of estradiol (o 30 pg/mL) or low levels of anti-Mullerian hormone ( o0.1 ng/mL).
RESULTS
From August 2000 to September 2013, 228 female patients underwent HSCT in our centre. Forty-seven patients (20.6%) underwent ovarian tissue cryopreservation. The other patients were excluded owing to parents' refusal, poor prognosis or a lower risk of subsequent infertility.
The patients' characteristics are summarised in Table 1 . Patients were affected by the following: Diamond-Blackfan anemia (n = 1), Ewing sarcoma (n = 3), immunodeficiency (n = 2), AML (n = 11), ALL (n = 14), CML (n = 5), non-Hodgkin lymphoma (n = 2), myelodisplastic syndrome (n = 2) or thalassemia (n = 7).
The median age at diagnosis was 11.1 years (range: 0-17.5 years). The median age at the time of the procedure was 13 years (range: 2.7-20.3 years).
Twenty-four patients (51%) were not pubertal at the time of storage, whereas 23 patients (49%) had already experienced menarche.
Laparoscopic surgery resulted in no acute or chronic complications.
Histological examination revealed no tumour contamination in any of the patients affected by malignant disease (n = 37).
Eleven patients (23.4%) had cryopreservation before undergoing any treatment, except for iron chelation in thalassemic patients (n = 7) and steroids in Diamond-Blackfan anemia(n = 1), whereas 36 patients (76.6%) had already received chemotherapy.
The median time between laparoscopy and HSCT was 25 days (range: 14-595 days). Conditioning regimens were TBI based (12 Gy) in 23 patients (48.9%), busulfan based in 21 patients (44.7%) and without TBI or busulfan in 3 patients (6.4%).
Five patients (10.6%) received additional treatment after HSCT: pelvic radiotherapy at 54 Gy (n = 2), lower limb radiotherapy at 54 Gy (n = 1), imatinib (n = 1) and second HSCT (n = 1).
The median follow-up time was 6.5 years (range: 0.3-13.7 years) and the median age at the last follow-up was 18.6 years (range: 5.5-29.4 years).
Forty patients (85.1%) were alive at the last follow-up, whereas seven (14.9%) were dead owing to disease progression or transplant-related mortality.
Hypogonadism Thirteen patients were not evaluable for hypogonadism owing to early age (10 patients), loss to follow-up (2 patients) and continuous treatment with estroprogestinics after transplant (1 patient).
Twenty-six out of 28 evaluable patients (93%) developed hypergonadotropic hypogonadism at a median of 23.3 months (range: 1.1-123.4 months) after the end of treatment. Clinical and laboratory findings are described in Table 2 . Twenty-five patients (96%) are undergoing estroprogestinic therapy.
The median age at diagnosis was 10.6 years (range: 0-16.9 years). The median age at cryopreservation was 13.6 years (range: 4.4-20.3 years). Fourteen patients (56%) who developed hypogonadism were pubertal at the time of cryopreservation.
The therapy before cryostorage consisted of polychemotherapy in 20 patients (80%), tyrosine kinase inhibitor treatment in 2 patients (8%), iron chelation in 2 patients (8%) and no therapy in 1 patient (4%).
Conditioning regimen was TBI based in 13 patients (52%) and busulfan based in 11 patients (44%).
Two patients have not, to date, developed hypogonadism, but no evaluation could be carried out on subsequent development of POF.
One patient is affected by CML, diagnosed at the age of 13.7 years, treated with oncocarbide before HSCT and with a TBI-based HSCT. She is now 23.8 years old, and is being treated with tyrosine kinase inhibitors, owing to a molecular relapse of the disease.
The second patient is affected by thalassemia and underwent a busulfan-based HSCT (busulfan dose 16 mg kg) at the age of 7.7 years. She is now 15.9 years old with regular menses. According to the disease, the median size of collected follicles was 25 mm 2 (range: 0-120 mm 2 ) in patients affected by malignant diseases and 30 mm 2 (range:12-120 mm 2 ) in those affected by non-malignant disease.
The median size in patients who subsequently developed hypogonadism was 25 mm 2 (range: 0-85 mm 2 ).
Pregnancies
One patient affected by thalassemia (patient 47) required autologous orthotopic transplantation of ovarian cortical tissue that resulted in one live birth, as previously reported. 22 The patient underwent HSCT with a busulfan-based conditioning regimen at the age of 21 years and experienced POF. Eight years later, the ovarian tissue was thawed and grafted during laparoscopy at an orthotopic site. The advantages of orthotopic transplantation include the possibility of natural conception, the favourable environment for follicular development and the proven efficacy in restoring fertility. 23 Three months after grafting, the decrease of circulating folliclestimulating hormone levels and the parallel increase of E2 levels demonstrated ovarian function restoration, which was confirmed by bidimensional ultrasound and colour Doppler examinations. After some ovulatory cycles, the patient spontaneously conceived 16 months after transplantation. After 39 weeks of uneventful gestation, a healthy girl weighing 3 970 g was born. 22 
DISCUSSION
Fertility after HSCT has become a topic of major concern in the past few years. The conditioning regimen (TBI and chemotherapy) before HSCT presents a high risk (480%) of subsequent infertility. 7, 9, 12 Abbreviations: BDA = Blackfan-Diamond Anemia; BU = busulfan; CT = chemotherapy; EP = estroprogestinic; FUP = follow-up; ID = immunodeficiency; MDS = Myelodysplastic syndrome; Na = not applicable; Ne = not evaluable; NHL = non-Hodgkin lymphoma; TKI = tyrosine kinase inhibitor.
Ovarian tissue cryopreservation in children E Biasin et al TBI and older age at treatment are well-known risk factors for subsequent hypogonadism, as well as busulfan administration, but no prediction can be made of the real risk of developing infertility. 7, 12, 24, 25 Since 2000, in our centre, we proposed an experimental protocol for ovarian tissue cryostorage to girls undergoing HSCT, to preserve future fertility.
Diverse series of ovarian tissue cryopreservation in girls have recently been reported. [26] [27] [28] [29] [30] [31] The number of patients ranged between 23 and 58 for each study. The surgical technique varied from whole ovary collection to multiple biopsies of the cortical tissue. The main goal was to evaluate the feasibility of the procedure.
To date, almost 30 live births have been reported worldwide after orthotopic autologous ovarian transplant 22, 24, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] whereas heterotopic grafting has led to one twin pregnancy, 48 a biochemical pregnancy 49 and four spontaneous pregnancies with three live births being described as a result of a reactivation of the native ovary. 50 The analysis of the recovery of ovarian function is difficult because of a lack of reports in the literature that indicate how many patients in the world have been subjected to transplantation of ovarian tissue. However, the recovery of ovarian function has been described in all published cases of ovarian transplantation, both orthotopic and heterotopic. Donnez et al. describe an average time of~3-4 months from graft to the recovery of ovarian function, in agreement with the timing of folliculogenesis. 33 At our centre, all the patients who had ovarian tissue cryopreservation presented a high risk of developing future infertility. The results showed a very high percentage of hypergonadotropic hypogonadism (93%) occurrence in the evaluable patients, and no current evaluation of POF could be done. This is a confirmation that the patients we selected were actually good candidates for ovarian tissue cryostorage, thus balancing possible surgical complications. Nonetheless, in our series, we reported no surgical complications, and the patients underwent subsequent HSCT only after a median time of 25 days from surgery.
Some of the previous reports also included patients with a low-medium risk of subsequent infertility, who had spontaneous pregnancies after treatments. In our opinion, ovarian tissue cryopreservation should not be offered to patients with a moderate risk of gonadotoxicity, as the surgical risk is not compensated by a real advantage in this group of patients.
No evaluation could be done on the follicle density of the collected tissue, nor could any correlation to previous therapy be found because of the low number of patients with the same characteristics.
The report of a live birth among our patients gave us a confirmation of the effectiveness of our technique of ovarian tissue retrieval, cryopreservation and transplantation. 22 Two problems should be argued: the possibility to restore hormonal ovarian function and tumour contamination of the cryopreserved tissue.
It has been reported that there are individual variations in the duration of endocrine functions after transplantation; ovarian function has been demonstrated to persist up to 7 years after transplantation with a mean duration of 4-5 years if follicular density is well preserved. 23 Ovarian tissue transplantation can represent an option to induce spontaneous puberty in prepubertal patients undergoing primitive hypogonadism, as has been recently reported, 51, 52 but this approach should be validated in the future.
Many authors have recently debated the risk of reimplanting ovarian tissue with tumour cell contamination. 53 Sommerzer et al. previously defined the risk of ovarian metastases according to cancer type with the higher risk for leukaemia, neuroblastoma and Burkitt lymphoma. 54 In particular, ovarian metastases have been found in up to 30% of ALL patients at autopsy, even if they are rarely clinically detected. 55 Recently, using disease-specific PCR techniques, Dolmans et al. found contamination of the ovarian tissue in 33% of CML patients and in 70% of ALL patients. 56 At the same time, Greve et al. reported that ovaries from leukaemia patients in complete remission do not appear to contain viable malignant cells, in contrast to ovarian tissue retrieved before chemotherapy. 57, 58 As far as our series of patients is concerned, no disease could be detected by histological examination of the tissue before cryostorage, even though it cannot be considered completely reassuring. That is why we experimentally evaluated by reverse transcription-PCR the expression of molecular translocations, when present at the diagnosis of the disease (n = 7), and no positivity has been found (data not shown).
However, it is now recommended that ovarian tissue autotransplantation should be discouraged when there is any risk of reimplanting malignant cells. 53 Other techniques such as isolated follicle transplantation, 59 in vitro follicular culture [60] [61] [62] and isolation of primordial follicles followed by transplantation of an alginate matrigel matrix containing isolated ovarian cells 58 require additional research before becoming available for humans.
In conclusion, even though ovarian tissue cryopreservation is still to be considered investigational, it does offer very encouraging results and represents the only option to preserve fertility in prepubertal girls.
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